Rosacea Causes and Mechanisms
Rosacea is not caused by one single factor. It is driven by a combination of vascular, immune, and skin barrier changes that make the skin more reactive. An estimated 415 million people worldwide live with rosacea, with prevalence rates of 5–10% in fair-skinned populations. Twin studies demonstrate approximately 50% heritability, and genome-wide association studies have identified specific risk loci linking rosacea to immune regulation and pigmentation pathways.
Key Mechanisms at a Glance
Neurovascular dysregulation
TRPV1/TRPA1 channel activation, cathelicidin overexpression, and angiogenesis drive flushing and persistent erythema.
Innate immune activation
Overexpressed KLK5 serine protease cleaves cathelicidin (LL-37) into pro-inflammatory fragments, sustaining chronic inflammation.
Demodex & microbiome
Mite densities up to 18× higher than controls; Bacillus oleronius proteins trigger neutrophilic inflammation.
Genetic susceptibility
GWAS identified risk loci at HLA-DRA, IRF4, and SLC45A2; twin-study heritability ~50%.
Vascular Mechanisms
TRPV1 & TRPA1 Ion Channels
Your skin has built-in sensors for heat and irritation — and in rosacea, those sensors are stuck on high alert, reacting to things that wouldn't bother most people. Transient receptor potential vanilloid 1 (TRPV1) channels are overexpressed in rosacea-affected skin. These channels respond to heat (>43°C), capsaicin, and low pH — classic rosacea triggers. When activated, they release vasoactive neuropeptides (substance P, CGRP) that dilate dermal blood vessels and recruit immune cells.[1]
TRPA1 channels, co-expressed on sensory neurons, respond to environmental irritants (alcohol metabolites, cinnamaldehyde). Their activation explains why seemingly unrelated stimuli — cold wind, certain cosmetics, red wine — all produce the same flushing response.[2]
Cathelicidin & KLK5 Pathway
Your skin naturally produces a protective protein designed to fight infection — but in rosacea, it gets massively overproduced and ends up causing the very inflammation it was meant to prevent. The antimicrobial peptide cathelicidin (hCAP18) is processed by kallikrein-5 (KLK5) serine protease into the active fragment LL-37. In rosacea patients, both KLK5 activity and cathelicidin levels are markedly elevated — up to 10× above normal in affected skin.[3]
LL-37 acts as a potent vasodilator and chemoattractant. It promotes angiogenesis (new blood vessel formation) and directly activates endothelial cells. This creates a self-reinforcing loop: more vessels → more blood flow → more visible redness. Yamasaki et al. (2007) demonstrated that injecting cathelicidin fragments into mouse skin reproduces rosacea-like inflammation.[3]
Angiogenesis & Vascular Remodelling
Over time, rosacea actually causes your skin to grow extra blood vessels — which is why flushing tends to get worse and last longer the longer you've had the condition. Chronic rosacea shows increased dermal vascular density. VEGF (vascular endothelial growth factor) is upregulated in rosacea skin, driving formation of new, structurally abnormal blood vessels that are more prone to dilation and leakage.[4]
These new vessels lack normal smooth-muscle control, making them poor at constricting when stimuli pass. This is why flushing episodes become longer over time — the vasculature itself is progressively remodelled. Laser and IPL treatments work partly by destroying these abnormal vessels.
Demodex Mite Research
Mite Density Studies
Demodex folliculorum mites live in hair follicles on normal skin, but their density is dramatically elevated in rosacea. Standardised skin surface biopsy (SSSB) studies consistently report ≥5 mites/cm² in rosacea patients versus <1/cm² in healthy controls. Casas et al. (2012) recorded a mean of 12.8 mites/cm² in papulopustular rosacea patients compared to 0.7/cm² in age-matched controls.[5]
This overpopulation is not uniformly distributed — it concentrates on the cheeks, nose, and chin, mirroring the typical rosacea distribution. A threshold of >5 mites/cm² is now widely accepted as clinically significant (Forton & Seys, 1993).[6]
Bacillus oleronius & Immune Activation
When Demodex mites die on your skin, they release bacteria that your immune system treats as a major threat — triggering the red, angry bumps that characterise papulopustular rosacea. The bacterium Bacillus oleronius, isolated from inside Demodex mites, produces proteins that stimulate a strong immune response in rosacea patients. Lacey et al. (2007) showed that 73% of rosacea patients had serum reactivity to B. oleronius antigens compared to 29% of controls.[7]
When mites die, they release these bacteria into the follicle, triggering TLR2-mediated neutrophil recruitment — explaining the papules and pustules seen in subtype 2 rosacea. This pathway activates NF-κB and promotes IL-8 and TNF-α secretion.[8]
A second organism, Staphylococcus epidermidis, is also found at altered ratios in the rosacea microbiome and may synergise with Demodex-associated inflammation.
Treatment Implications
The Demodex hypothesis is supported by therapeutic evidence. Topical ivermectin (1% cream) — an anti-parasitic — is now a first-line treatment for papulopustular rosacea. In the ATTRACT trial, ivermectin outperformed metronidazole (the previous standard) at 16 weeks, with 84% of patients achieving clear or almost-clear skin.[9]
Oral ivermectin and tea tree oil (which contains terpinen-4-ol, toxic to Demodex) also show efficacy, further supporting the causal role of mite overpopulation in at least the papulopustular subtype.
Genetic Studies
Heritability & Family Studies
Rosacea has a strong heritable component. A Danish twin-registry study estimated heritability at ~46%, meaning roughly half of rosacea susceptibility is explained by genetic factors.[10] Family-based studies show a 4-fold increased risk among first-degree relatives of rosacea patients.
The condition is most prevalent in individuals of Northern European descent (particularly Celtic and Scandinavian ancestry), supporting a genetic founder effect related to lighter skin pigmentation and associated immune–pigmentation gene variants.
Genome-Wide Association Studies (GWAS)
A GWAS is a study that scans the DNA of thousands of people to find specific genetic variations that are more common in those with a particular condition — essentially asking "which bits of DNA make rosacea more likely?" Two landmark GWAS have identified key rosacea risk loci:
- •HLA-DRA (6p21.32) — The strongest signal maps to the major histocompatibility complex class II region, implicating adaptive immune antigen presentation. This locus is shared with type 1 diabetes, celiac disease, and multiple sclerosis.[11]
- •IRF4 (6p25.3) — Interferon regulatory factor 4, involved in immune cell differentiation and pigmentation. Also a melanoma and freckling susceptibility gene.[11]
- •SLC45A2 (5p13.2) — A membrane-associated transporter protein linked to lighter skin pigmentation. Variants in this gene are associated with sun sensitivity and higher UV damage susceptibility.[12]
- •BTNL2 (6p21.3) — A butyrophilin-like gene involved in T-cell co-stimulation, also associated with sarcoidosis and inflammatory bowel disease.[12]
Chang et al. (2015) and Aponte et al. (2018) together identified these loci from cohorts totalling >70,000 individuals, confirming that rosacea shares genetic architecture with both autoimmune conditions and pigmentation traits.
Clinical Significance
The genetic overlap with autoimmune and pigmentation pathways explains two clinical observations: (1) rosacea patients have higher rates of co-morbid conditions like inflammatory bowel disease, cardiovascular disease, and migraines[13]; and (2) lighter-skinned individuals are disproportionately affected. These findings are shifting the understanding of rosacea from a purely dermatological condition toward a systemic inflammatory phenotype with multi-organ implications.
Triggers vs Causes
Triggers spark individual flares. Causes are the underlying biological drivers that make you susceptible.
Triggers (episodic)
- • Heat, UV, and weather shifts
- • Alcohol, capsaicin, hot drinks
- • Psychological stress, intense exercise
- • Skincare irritants (SLS, fragrance)
Causes (chronic)
- • TRPV1/cathelicidin vascular pathway
- • Demodex overpopulation & B. oleronius
- • HLA/IRF4 genetic risk variants
- • Barrier defect (ceramide depletion)
Learn how to identify your personal triggers in the triggers & tracking guide.
Why understanding causes matters
Matching treatment to mechanism is key. Vascular-dominant rosacea responds best to brimonidine and laser therapy. Demodex-driven papulopustular disease clears with ivermectin. Knowing which pathway drives your symptoms avoids months of trial-and-error with mismatched treatments.
References
- Sulk M, Seeliger S, Auber J, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012;132(4):1253-1262.
- Tóth BI, Oláh A, Szöllősi AG, Bíró T. TRP channels in the skin. Br J Pharmacol. 2014;171(10):2568-2581.
- Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980.
- Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008;300(3):125-131.
- Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906-910.
- Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardised skin-surface biopsy. Br J Dermatol. 1993;128(6):650-659.
- Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474-481.
- O'Reilly N, Menezes N, Kavanagh K. Positive correlation between serum immunoreactivity to Demodex-associated Bacillus proteins and erythematotelangiectatic rosacea. Br J Dermatol. 2012;167(5):1032-1036.
- Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea (ATTRACT). Br J Dermatol. 2015;172(4):1103-1110.
- Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151(11):1213-1219.
- Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135(6):1548-1555.
- Aponte JL, Chiano MN, Engel C, et al. Identification of rosacea susceptibility loci using genome-wide association data from the 23andMe research cohort. J Invest Dermatol. 2018;138(Suppl):S169.
- Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016;74(4):667-672.